Anatomic Stage III Breast Cancer AJCC v8 Clinical Trials in Atlanta, Georgia

5 studies are recruiting for anatomic stage iii breast cancer ajcc v8 in Atlanta, Georgia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

   This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Grady Health System, Atlanta, Georgia

   Locations

   556 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06058377 on ClinicalTrials.gov

2. Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer

   This early phase I trial tests whether letrozole with simvastatin works better than letrozole alone to stop tumor cell proliferation in patients with stage I-III hormone receptor positive, HER2 negative invasive breast cancer. Letrozole and simvastatin may stop the growth of cancer cells by blockin…

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   Grady Healthcare System, Atlanta, Georgia

   Locations

   4 in total

   Run by

   Emory University

   See if you can join NCT05464810 on ClinicalTrials.gov

3. Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer

   This phase II trial tests how well propranolol and pembrolizumab work to cause tumor re-sensitization and therefore treatment in patients with triple negative breast cancer that has not responded to previous checkpoint inhibitor therapy (refractory), cannot be removed by surgery (unresectable) or h…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Emory University Hospital, Atlanta, Georgia

   Locations

   2 in total

   Run by

   Emory University

   See if you can join NCT05741164 on ClinicalTrials.gov

4. Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer

   This clinical trial evaluates if in-person acupuncture or virtual acupressure therapy prevents aromatase inhibitor-associated joint pain in Non-Hispanic Black postmenopausal women with stage I-III (early-stage) hormone receptor positive (HR+) breast cancer. Aromatase inhibitors (AI) are medications…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Grady Health System, Atlanta, Georgia

   Locations

   4 in total

   Run by

   Emory University

   See if you can join NCT06534125 on ClinicalTrials.gov

5. Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

   This phase I trial tests the safety, side effects, and best dose of a personalized vaccine (tumor membrane vesicle or TMV vaccine) by itself and in combination with checkpoint inhibitor (pembrolizumab or ipilimumab) in treating patients with triple negative breast cancer. This vaccine is made by ta…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Grady Health System, Atlanta, Georgia

   Locations

   4 in total

   Run by

   Emory University

   See if you can join NCT06324240 on ClinicalTrials.gov